Pharmamarketeer

Ardelyx’s Ibsrela wins FDA approval for IBS-C

Ardelyx announced that it has received FDA approval for its NHE3 sodium transport inhibitor Isbrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Isbrela is a 50mg, twice daily oral pill that is a minimally absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients.

read more

Medhc-fases-banner
Advertentie(s)